Literature DB >> 16865308

Long-term anti-TNFalpha therapy for ankylosing spondylitis in two patients with chronic HBV infection.

Grigorios T Sakellariou1, Ioannis Chatzigiannis.   

Abstract

Anti-TNFalpha therapy for rheumatic diseases appears to be safe in patients with chronic hepatitis C. However, the administration of anti-TNFalpha agents without initiation of prophylactic antiviral therapy (lamivudine 100 mg/day) in patients with chronic HBV infection results in exacerbation of liver disease. In this report, we describe our experience of long-term anti-TNFalpha therapy for ankylosing spondylitis in two inactive HBsAg carriers without preemptive antiviral treatment.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16865308     DOI： 10.1007/s10067-006-0392-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   3.650


  11 in total

1.  Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

Authors:  P Ostuni; C Botsios; L Punzi; P Sfriso; S Todesco
Journal:  Ann Rheum Dis       Date:  2003-07       Impact factor: 19.103

2.  Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection.

Authors:  María del Valle García-Sánchez; Federico Gómez-Camacho; Antonio Poyato-González; Eva María Iglesias-Flores; Juan Francisco de Dios-Vega; Rocio Sancho-Zapatero
Journal:  Inflamm Bowel Dis       Date:  2004-09       Impact factor: 5.325

3.  Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B.

Authors:  Yoshitaka Ueno; Shinji Tanaka; Masaru Shimamoto; Yoshihiro Miyanaka; Toru Hiyama; Masanori Ito; Yasuhiko Kitadai; Masaharu Yoshihara; Masaharu Sumii; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

4.  Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?

Authors:  Gunda Millonig; Michaela Kern; Othmar Ludwiczek; Karin Nachbaur; Wolfgang Vogel
Journal:  World J Gastroenterol       Date:  2006-02-14       Impact factor: 5.742

5.  Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.

Authors:  L G Guidotti; T Ishikawa; M V Hobbs; B Matzke; R Schreiber; F V Chisari
Journal:  Immunity       Date:  1996-01       Impact factor: 31.745

6.  Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.

Authors:  C H Roux; O Brocq; V Breuil; C Albert; L Euller-Ziegler
Journal:  Rheumatology (Oxford)       Date:  2006-04-07       Impact factor: 7.580

Review 7.  Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J W J Bijlsma; M Dougados; P Emery; E C Keystone; L Klareskog; P J Mease
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 8.  Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection.

Authors:  L H Calabrese; N Zein; D Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

9.  Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C.

Authors:  Owonayo Oniankitan; Christophe Duvoux; Dominique Challine; Arianne Mallat; Xavier Chevalier; Jean-Michel Pawlotsky; Pascal Claudepierre
Journal:  J Rheumatol       Date:  2004-01       Impact factor: 4.666

10.  Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis.

Authors:  M Esteve; C Saro; F González-Huix; F Suarez; M Forné; J M Viver
Journal:  Gut       Date:  2004-09       Impact factor: 23.059
View more
  10 in total

Review 1.  Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.

Authors:  D C Sadowski; C N Bernstein; A Bitton; K Croitoru; R N Fedorak; A Griffiths
Journal:  Can J Gastroenterol       Date:  2009-03       Impact factor: 3.522

2.  Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases.

Authors:  Han Hee Ryu; Eun Young Lee; Kichul Shin; In Ah Choi; Yun Jong Lee; Bin Yoo; Min-Chan Park; Yong-Beom Park; Sang-Cheol Bae; Wan Hee Yoo; Sung Il Kim; Eun Bong Lee; Yeong Wook Song
Journal:  Clin Rheumatol       Date:  2012-02-17       Impact factor: 2.980

Review 3.  Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Authors:  Shunsuke Mori; Shigetoshi Fujiyama
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

Review 4.  Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action.

Authors:  Matthew B Carroll; Michael A Forgione
Journal:  Clin Rheumatol       Date:  2010-06-16       Impact factor: 2.980

5.  Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?

Authors:  Jinoos Yazdany; Leonard Calabrese
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

Review 6.  Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy.

Authors:  María Luisa Manzano-Alonso; Gregorio Castellano-Tortajada
Journal:  World J Gastroenterol       Date:  2011-03-28       Impact factor: 5.742

7.  Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports.

Authors:  Primal P Kaur; Virginia C Chan; Steven N Berney
Journal:  Clin Rheumatol       Date:  2008-06-03       Impact factor: 2.980

8.  Hepatitis B virus reactivation in a juvenile rheumatoid arthritis patient under treatment and its successful management: a complicated case.

Authors:  Oguz Durmus; Levent Tekin; Alparslan Bayram Carli; Engin Cakar; Ali Acar; Asim Ulcay; Umit Dincer; Mehmet Zeki Kiralp
Journal:  Rheumatol Int       Date:  2011-11-16       Impact factor: 3.580

Review 9.  Treatment of rheumatic diseases and hepatitis B virus coinfection.

Authors:  Anna Felis-Giemza; Marzena Olesińska; Katarzyna Świerkocka; Ewa Więsik-Szewczyk; Ewa Haładyj
Journal:  Rheumatol Int       Date:  2014-12-31       Impact factor: 2.631

10.  Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients.

Authors:  Caroline Charpin; Sandrine Guis; Philippe Colson; Patrick Borentain; Jean-Pierre Mattéi; Patrice Alcaraz; Nathalie Balandraud; Benoit Thomachot; Jean Roudier; René Gérolami
Journal:  Arthritis Res Ther       Date:  2009-11-26       Impact factor: 5.156
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.